Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Accounts Payables: 2010-2024

Historic Accounts Payables for Iovance Biotherapeutics (IOVA) over the last 10 years, with Dec 2024 value amounting to $27.5 million.

  • Iovance Biotherapeutics' Accounts Payables was N/A to $31.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.2 million, marking a year-over-year change of. This contributed to the annual value of $27.5 million for FY2024, which is 16.95% down from last year.
  • According to the latest figures from FY2024, Iovance Biotherapeutics' Accounts Payables is $27.5 million, which was down 16.95% from $33.1 million recorded in FY2023.
  • Over the past 5 years, Iovance Biotherapeutics' Accounts Payables peaked at $33.1 million during FY2023, and registered a low of $27.5 million during FY2024.
  • For the 2-year period, Iovance Biotherapeutics' Accounts Payables averaged around $30.3 million, with its median value being $30.3 million (2023).
  • Data for Iovance Biotherapeutics' Accounts Payables shows a maximum YoY declined of 16.95% (in 2024) over the last 5 years.
  • Over the past 2 years, Iovance Biotherapeutics' Accounts Payables (Yearly) stood at $33.1 million in 2023, then decreased by 16.95% to $27.5 million in 2024.